88 related articles for article (PubMed ID: 17211520)
1. Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib.
Drechsler M; Hildebrandt B; Kündgen A; Germing U; Royer-Pokora B
Ann Hematol; 2007 May; 86(5):353-4. PubMed ID: 17211520
[No Abstract] [Full Text] [Related]
2. Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.
Cavazzini F; Bardi A; Ciccone M; Rigolin GM; Gorello P; La Starza R; Mecucci C; Cuneo A
Cancer Genet Cytogenet; 2009 Oct; 194(1):67-9. PubMed ID: 19737658
[No Abstract] [Full Text] [Related]
3. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
Gunby RH; Cazzaniga G; Tassi E; Le Coutre P; Pogliani E; Specchia G; Biondi A; Gambacorti-Passerini C
Haematologica; 2003 Apr; 88(4):408-15. PubMed ID: 12681968
[TBL] [Abstract][Full Text] [Related]
4. Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report.
Pitini V; Arrigo C; Teti D; Barresi G; Righi M; Alo G
Haematologica; 2003 May; 88(5):ECR18. PubMed ID: 12745287
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
6. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).
Walz C; Haferlach C; Hänel A; Metzgeroth G; Erben P; Gosenca D; Hochhaus A; Cross NC; Reiter A
Genes Chromosomes Cancer; 2009 Feb; 48(2):179-83. PubMed ID: 19006078
[TBL] [Abstract][Full Text] [Related]
7. Sustained response to low-dose imatinib mesylate in a patient with chronic myelomonocytic leukemia with t(5;12)(q33;p13).
Shin J; Kim M; Kim DB; Yeom JO; Lee HJ; Cho SG
Acta Haematol; 2008; 119(1):57-9. PubMed ID: 18268406
[No Abstract] [Full Text] [Related]
8. Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.
Bastie JN; Garcia I; Terré C; Cross NC; Mahon FX; Castaigne S
Haematologica; 2004 Oct; 89(10):1263-4. PubMed ID: 15477214
[TBL] [Abstract][Full Text] [Related]
9. TV6 and PDGFRB: a license to fuse.
Lierman E; Cools J
Haematologica; 2007 Feb; 92(2):145-7. PubMed ID: 17296561
[No Abstract] [Full Text] [Related]
10. Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
Tefferi A; Kantarjian H
Am J Hematol; 2008 Mar; 83(3):175-7. PubMed ID: 18181199
[No Abstract] [Full Text] [Related]
11. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
12. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
Michor F
Trends Pharmacol Sci; 2007 May; 28(5):197-9. PubMed ID: 17412430
[TBL] [Abstract][Full Text] [Related]
13. A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome.
La Starza R; Rosati R; Roti G; Gorello P; Bardi A; Crescenzi B; Pierini V; Calabrese O; Baens M; Folens C; Cools J; Marynen P; Martelli MF; Mecucci C; Cuneo A
Leukemia; 2007 Apr; 21(4):830-3. PubMed ID: 17301821
[No Abstract] [Full Text] [Related]
14. [Targeted therapy of dermatofibrosarcoma with imatinib].
Ugurel S
J Dtsch Dermatol Ges; 2007 Mar; 5(3):261. PubMed ID: 17338806
[No Abstract] [Full Text] [Related]
15. The biology of chronic myelogenous leukemia: implications for imatinib therapy.
Alvarez RH; Kantarjian H; Cortes JE
Semin Hematol; 2007 Jan; 44(1 Suppl 1):S4-14. PubMed ID: 17292736
[TBL] [Abstract][Full Text] [Related]
16. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
17. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
Levine RL; Wadleigh M; Sternberg DW; Wlodarska I; Galinsky I; Stone RM; DeAngelo DJ; Gilliland DG; Cools J
Leukemia; 2005 Jan; 19(1):27-30. PubMed ID: 15496975
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella AM
Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
[No Abstract] [Full Text] [Related]
19. A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5).
Ghazzawi M; Mehra V; Knut M; Brown L; Tapper W; Chase A; de Lavallade H; Cross NCP
Acta Haematol; 2017; 138(4):198-200. PubMed ID: 29169164
[No Abstract] [Full Text] [Related]
20. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
Guida T; Anaganti S; Provitera L; Gedrich R; Sullivan E; Wilhelm SM; Santoro M; Carlomagno F
Clin Cancer Res; 2007 Jun; 13(11):3363-9. PubMed ID: 17545544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
